Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

Niu G, Li Z, Xie J, Le QT, Chen X.

J Nucl Med. 2009 Jul;50(7):1116-23. doi: 10.2967/jnumed.109.061820. Epub 2009 Jun 12.

2.

Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.

Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X.

Clin Cancer Res. 2010 Apr 1;16(7):2095-105. doi: 10.1158/1078-0432.CCR-09-2495. Epub 2010 Mar 9.

3.

177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.

Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F.

Mol Pharm. 2014 Mar 3;11(3):800-7. doi: 10.1021/mp4005047. Epub 2014 Feb 3.

PMID:
24472064
4.

Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.

Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, Chen X, Wang F.

Mol Cancer Ther. 2010 Aug;9(8):2297-308. doi: 10.1158/1535-7163.MCT-10-0444. Epub 2010 Aug 3.

5.

Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.

Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ.

J Nucl Med. 2008 Sep;49(9):1472-9. doi: 10.2967/jnumed.108.052316. Epub 2008 Aug 14.

6.

Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.

Day KE, Sweeny L, Kulbersh B, Zinn KR, Rosenthal EL.

Mol Imaging Biol. 2013 Dec;15(6):722-9. doi: 10.1007/s11307-013-0652-9.

7.

Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.

Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, Boerman OC.

Int J Cancer. 2011 Aug 15;129(4):870-8. doi: 10.1002/ijc.25727. Epub 2010 Dec 1.

8.

PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.

van Dijk LK, Yim CB, Franssen GM, Kaanders JH, Rajander J, Solin O, Grönroos TJ, Boerman OC, Bussink J.

Contrast Media Mol Imaging. 2016 Jan-Feb;11(1):65-70. doi: 10.1002/cmmi.1659. Epub 2015 Aug 4.

PMID:
26242487
9.

Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.

van Dijk LK, Boerman OC, Franssen GM, Lok J, Kaanders JH, Bussink J.

J Nucl Med. 2014 Oct;55(10):1665-70. doi: 10.2967/jnumed.114.141762. Epub 2014 Sep 18.

10.

Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.

Achmad A, Hanaoka H, Yoshioka H, Yamamoto S, Tominaga H, Araki T, Ohshima Y, Oriuchi N, Endo K.

Cancer Sci. 2012 Mar;103(3):600-5. doi: 10.1111/j.1349-7006.2011.02166.x. Epub 2011 Dec 23.

11.

64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-panitumumab.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jun 25 [updated 2010 Sep 30].

12.

Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.

Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ.

Cancer Biother Radiopharm. 2008 Apr;23(2):158-71. doi: 10.1089/cbr.2007.0444.

PMID:
18454685
13.

MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.

Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.

Nucl Med Biol. 2015 Feb;42(2):71-7. doi: 10.1016/j.nucmedbio.2014.10.009. Epub 2014 Oct 22.

PMID:
25456837
14.

86Y-CHX-A''-diethylenetriamine pentaacetic acid-panitumumab.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Aug 25 [updated 2011 Dec 8].

15.

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, Lammertsma AA, van Dongen GA.

J Nucl Med. 2003 Oct;44(10):1663-70.

17.

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody.

Cai W, Chen K, He L, Cao Q, Koong A, Chen X.

Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8. Epub 2007 Jan 30.

PMID:
17262214
18.

177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.

Hoppmann S, Qi S, Miao Z, Liu H, Jiang H, Cutler CS, Bao A, Cheng Z.

J Biol Inorg Chem. 2012 Jun;17(5):709-18. doi: 10.1007/s00775-012-0890-3. Epub 2012 Mar 16.

PMID:
22418921
19.

Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.

Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD.

Nucl Med Biol. 2013 May;40(4):451-7. doi: 10.1016/j.nucmedbio.2013.01.007. Epub 2013 Feb 27.

20.

Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.

Miao Z, Ren G, Liu H, Jiang L, Cheng Z.

Bioconjug Chem. 2010 May 19;21(5):947-54. doi: 10.1021/bc900515p.

PMID:
20402512

Supplemental Content

Support Center